| pubmed-article:3195322 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3195322 | lifeskim:mentions | umls-concept:C0021494 | lld:lifeskim |
| pubmed-article:3195322 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:3195322 | lifeskim:mentions | umls-concept:C0060520 | lld:lifeskim |
| pubmed-article:3195322 | lifeskim:mentions | umls-concept:C0060525 | lld:lifeskim |
| pubmed-article:3195322 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:3195322 | pubmed:dateCreated | 1989-1-5 | lld:pubmed |
| pubmed-article:3195322 | pubmed:abstractText | After intravenous injection of fluorescein the time-course of the plasma concentrations of fluorescein (F) and fluorescein glucuronide (FG) was studied in 18 insulin-dependent diabetics with various degrees of nephropathy, and in two non-diabetic subjects. Fifteen minutes after injection the molar concentrations of free (non-protein bound) F and FG were almost identical. After one hour the concentration curve integrals of the two substances were of the same magnitude. There was, however, considerable interindividual variation. In diabetic patients with renal insufficiency an increase was found in both integrals, the F integral being less increased (27%) than the FG integral (44%). It appears from the variation in absolute and relative concentrations of F and FG that a separate determination of the two fluorophores in plasma is desirable, when F is used by intravenous administration as an indicator of blood-ocular barrier function. Previous observations of an increase with time after injection of the free fraction of plasma fluorescence are explained by the finding of a higher free fraction of FG (34%) than of F (11%) and a change in relative concentrations of the two fluorophores. | lld:pubmed |
| pubmed-article:3195322 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3195322 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3195322 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3195322 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3195322 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3195322 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3195322 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3195322 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3195322 | pubmed:issn | 0001-639X | lld:pubmed |
| pubmed-article:3195322 | pubmed:author | pubmed-author:LarsenMM | lld:pubmed |
| pubmed-article:3195322 | pubmed:author | pubmed-author:Lund-Andersen... | lld:pubmed |
| pubmed-article:3195322 | pubmed:author | pubmed-author:HommelEE | lld:pubmed |
| pubmed-article:3195322 | pubmed:author | pubmed-author:LoftSS | lld:pubmed |
| pubmed-article:3195322 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3195322 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:3195322 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3195322 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3195322 | pubmed:pagination | 427-32 | lld:pubmed |
| pubmed-article:3195322 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:meshHeading | pubmed-meshheading:3195322-... | lld:pubmed |
| pubmed-article:3195322 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3195322 | pubmed:articleTitle | Fluorescein and fluorescein glucuronide in plasma after intravenous injection of fluorescein. | lld:pubmed |
| pubmed-article:3195322 | pubmed:affiliation | Department of Ophthalmology, Gentofte Hospital, Hellerup, Denmark. | lld:pubmed |
| pubmed-article:3195322 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3195322 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
